Results from the TheraP Phase 2 trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel (Jevtana), according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
The data also demonstrated that grade 3 or 4 side effects, which are considered serious or severe, were less common in patients who received LuPSMA. PSA-progression-free survival (PSA-PFS) favored LuPSMA as well. The randomized phase II trial included men with mCRPC post docetaxel suitable for cabazitaxel, progressive disease with rising PSA and PSA ≥ 20 ng/mL. Prior to admission to the trial, Imaging with PSMA radiotracers had to confirm that the patients’ tumors had high PSMA-expression to be eligible.
The PSA response rate was higher in patients who received LuPSMA than those who received cabazitaxel (66% vs 37%; P< 0.001). This represented a 29%, (P< 0.0001) absolute greater PSA response rate in participants receiving LuPSMA compared to cabazitaxel.
You can read the full news release here: http://tiny.cc/CURE-News-LuPSMA